Liquidia Corp
NASDAQ:LQDA
Liquidia Corp
Revenue
Liquidia Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liquidia Corp
NASDAQ:LQDA
|
Revenue
$14m
|
CAGR 3-Years
3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$88.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$63.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$64.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$45B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Liquidia Corp
Revenue Breakdown
Breakdown by Geography
Liquidia Corp
Breakdown by Segments
Liquidia Corp
|
Total Revenue:
14m
USD
|
|
Represents Information Pertaining To Single R...:
14m
USD
|
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
What is Liquidia Corp's Revenue?
Revenue
14m
USD
Based on the financial report for Dec 31, 2024, Liquidia Corp's Revenue amounts to 14m USD.
What is Liquidia Corp's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was -20%. The average annual Revenue growth rates for Liquidia Corp have been 3% over the past three years , 12% over the past five years .
You don't have any saved screeners yet